Inicia sesión Registrate Mi Biblioteca biblioteca abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.

Tratamiento no farmacológico

404 ARTíCULOS , VIENDO DEL 106 AL 120

PUBMED

Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease

Agrawal M, Ajazuddin, Tripathi DK, Saraf S, Saraf S, Antimisiaris SG, Mourtas S, Hammarlund-Udenaes M, Alexander A.

J Control Release. 2017 Aug 28;260:61-77. doi: 10.1016/j.jconrel.2017.05.019. Epub 2017 May 24.

0

0

0

PUBMED

Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease

Hsu CW, Lee Y, Lee CY, Lin PY.

Clin Neuropharmacol. 2017 May/Jun;40(3):147-148. doi: 10.1097/WNF.0000000000000215.

0

0

0

PUBMED

Novel Treatment Strategies Using TiO(2)-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease

Sharma A, Menon PK, Patnaik R, Muresanu DF, Lafuente JV, Tian ZR, Ozkizilcik A, Castellani RJ, Mössler H, Sharma HS.

Int Rev Neurobiol. 2017;137:123-165. doi: 10.1016/bs.irn.2017.09.002. Epub 2017 Nov 6.

0

0

0

PUBMED

Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease

Musaeus CS, Shafi MM, Santarnecchi E, Herman ST, Press DZ.

J Alzheimers Dis. 2017;58(4):1065-1076. doi: 10.3233/JAD-160742.

0

0

0

PUBMED

Improved learning of sequential behaviour during cane gait training or stair climbing after femoral neck fracture: an implication for donepezil for very mild Alzheimer's disease

Kumai K, Nakamura K, Meguro K.

Psychogeriatrics. 2017 Mar;17(2):144-145. doi: 10.1111/psyg.12204. Epub 2016 Jul 13.

0

0

0

PUBMED

Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer's Disease in South Korea: RECAP Study Results

Lee KJ, Cho SJ, Kim BC, Park M, Lee JH.

Adv Ther. 2017 Feb;34(2):481-494. doi: 10.1007/s12325-016-0465-8. Epub 2016 Dec 20.

0

0

0

PUBMED

Carriers of an apolipoprotein E epsilon 4 allele are more vulnerable to a dietary deficiency in omega-3 fatty acids and cognitive decline

Nock TG, Chouinard-Watkins R, Plourde M.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Oct;1862(10 Pt A):1068-1078. doi: 10.1016/j.bbalip.2017.07.004. Epub 2017 Jul 18.

0

0

0

PUBMED

Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview

Kumar A, Singh A, Aggarwal A.

Indian J Exp Biol. 2017 Feb;55(2):63-73.

0

0

0

PUBMED

Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease

Koponen M, Taipale H, Lavikainen P, Tanskanen A, Tiihonen J, Tolppanen AM, Ahonen R, Hartikainen S.

J Clin Psychiatry. 2017 Mar;78(3):e257-e263. doi: 10.4088/JCP.15m10458.

0

0

0

PUBMED

Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years

Wattmo C, Wallin ÅK.

Alzheimers Res Ther. 2017 Aug 31;9(1):70. doi: 10.1186/s13195-017-0294-2.

0

0

0

PUBMED

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L, Olsson T, Ye N, Rosen L, Russell M, Maltby J, Eketjäll S, Kugler AR.

J Alzheimers Dis. 2017;55(3):1039-1053. doi: 10.3233/JAD-160701.

0

0

0

PUBMED

New Tacrines as Anti-Alzheimer's Disease Agents. The (Benzo)Chromeno- PyranoTacrines

Oset-Gasque MJ, Marco-Contelles J.

Curr Top Med Chem. 2017;17(31):3349-3360. doi: 10.2174/1568026618666180112155928.

0

0

0

PUBMED

Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction

Hishikawa N, Fukui Y, Sato K, Ohta Y, Yamashita T, Abe K.

Geriatr Gerontol Int. 2017 Oct;17(10):1384-1391. doi: 10.1111/ggi.12870. Epub 2016 Aug 31.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neuroacademy